Dr Dolan reports consultant fees from MyoKardia, Genentech, Puma Biotechnology, Gilead Sciences, Alexion Pharmaceuticals, Portola Pharmaceuticals, Halozyme Therapeutics, Global Blood Therapeutics, and REGENXBIO. Dr Fine is an employee of Bristol Myers Squibb at the time of this article development; and reports stock and stock options from the company. Dr Masri reports research grants from Pfizer, Akcea, Ionis, Ultromics, and the Wheeler Foundation; as well as fees (consulting or honoraria) from Eidos, Pfizer, Ionis, Bristol Myers Squibb, Attralus, Tenaya, Alnylam, and Cytokinetics. Dr Saberi reports consulting fees from MyoKardia and Cytokinetics. Dr Wang reports consultant fees from MyoKardia and personal fees from Cytokinetics. Dr Elliot reports consultant and personal fees from MyoKardia, Sanofi, AstraZeneca, Pfizer, and DinaQor; and patent No. GB1815111.8 issued to his institution. Dr Hegde reports that her institution received payments for her consulting work from MyoKardia. Drs Lam and Sehnert are employees of Bristol Myers Squibb and report stock and stock options from the company. Dr Cresci reports that her institution received clinical trial funding from Imbria Pharmaceuticals; and membership on the Data Monitoring Committee for Cytokinetics. Dr Bach reports institutional funding for clinical trials by MyoKardia/Bristol Myers Squibb and Cytokinetics. Dr Spertus reports consultative services on patient-reported outcomes and evidence evaluation for Alnylam, AstraZeneca, Bayer, Merck, Janssen, Bristol Meyers Squibb, Edwards, Kineksia, 4DT Medical, Terumo, Cytokinetics, Imbria, and United Healthcare. He holds research grants from Bristol Meyers Squibb, Abbott Vascular, and Janssen. He owns the copyright to the Seattle Angina Questionnaire, Kansas City Cardiomyopathy Questionnaire, and Peripheral Artery Questionnaire and serves on the Board of Directors for Blue Cross Blue Shield of Kansas City. The other authors report no disclosures.